<DOC>
	<DOCNO>NCT01358422</DOCNO>
	<brief_summary>Research question : 1 . What absolute risk reduction in-hospital major adverse cardiac event ( MACE ) associate use dual anti-platelet therapy compare aspirin alone population ? 2 . What absolute risk increase clinically significant bleeding period associate use dual anti-platelet therapy compare aspirin alone population ? In brief design study follow : - We study patient undergo non-cardiac surgery within four year coronary stenting . - We record anti-platelet agent take patient , surgery . - We record cardiac bleeding event occur whilst patient hospital . - We use statistical technique propensity score match patient similar risk factor receive different anti-platelet regimen . - We compare incidence cardiac event bleed match group .</brief_summary>
	<brief_title>Occurrence Bleeding Thrombosis During Antiplatelet Therapy Non-cardiac Surgery</brief_title>
	<detailed_description>This study compare use aspirin alone dual antiplatelet therapy ( i.e . aspirin clopidogrel ) patient present elective non-cardiac surgery undergone PCI either bare metal stent drug elute stent placement four year prior surgery . The absolute risk reduction major adverse cardiac event ( MACE ) dual antiplatelet therapy absolute risk increase clinically significant bleed event dual therapy determine . This allow number need treat ( NNT ) prevention MACE number need harm ( NNH ) bleeding determine optimal antiplatelet therapy set identify .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Patients undergo noncardiac surgery within four year percutaneous coronary intervention ( PCI ) placement bare metal drug elute stent include study . Patients maintain anticoagulant therapy e.g . heparin infusion surgery exclude . ( Patients receive prophylactic dos heparin prevention thromboembolic event eligible inclusion . ) Patients receive bridge therapy full anticoagulant heparin drug compensate withdrawal antiplatelet drug exclude . Patients anticoagulated warfarin ( INR &gt; 1.5 time surgery ) exclude . Patients receive full anticoagulation heparin know recent know thromboembolic event ( APPT ratio &gt; 1.5 ) exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Prospective observational study</keyword>
	<keyword>major adverse cardiac event ( MACE )</keyword>
	<keyword>clinically significant bleeding event</keyword>
	<keyword>Dual anti-platelet therapy</keyword>
	<keyword>aspirin alone therapy</keyword>
	<keyword>non-cardiac surgery</keyword>
	<keyword>percutaneous coronary intervention ( PCI )</keyword>
	<keyword>placement bare metal drug eluting stent</keyword>
	<keyword>OBTAIN</keyword>
	<keyword>Simon Howell</keyword>
	<keyword>ESA</keyword>
	<keyword>European Society Anaesthesiology</keyword>
</DOC>